Protein Kinase Targets 2009

JOIN OVER 125 OF YOUR COLLEAGUES AT THIS MUST-ATTEND EVENT!

Targeting kinase inhibitors and developing novel drug designs has become very attractive for the pharmaceutical industry. Numerous drugs are in phase 3 and beyond and due to the complexity of the kinome, there are still many opportunities for developing novel inhibitors. In order to stay ahead of the competition it is necessary to keep up to date on the current state of the art on lead compounds as well as on the newest developments in structure based drug design and the current assay technologies. In addition, discussions on target validation, on how to bring sense into the chemical space and on how to analyze the flood of data available will be presented.

KEYNOTE SPEAKER
To be or not to be Selective? What the Past 10 Years have Taught us about Developing Effective Kinase Inhibitors
Isabelle Dussault, Ph.D., Director of Research, Amgen

NEW this year:
Opportunity to Network and Brainstorm in TWO Moderated and Dedicated Breakout Discussion Sessions

Participating Companies:

Amgen Inc.
Ariad Pharmaceuticals
AstraZeneca
Aureus Pharma
Bayer Schering Pharma AG
Bristol-Myers Squibb Co.
GlaxoSmithKline
MedImmune Inc.
OSI Pharmaceuticals
Schering-Plough Research Institute
SuperGen
Wyeth
and more

 
For more information, please contact:
Margit Eder, Ph.D. Conference Director
Phone: 781-972-5478    Email: meder@healthtech.com

For sponsorship or exhibiting information, please contact: 
Katelin Fitzgerald, Manager, Business Development
Phone: 781-972-5458   Email: kfitzgerald@healthtech.com